الفهرس 
Possible pharmacological effects of certain complementary therapies on experimentally induced Parkinson’s disease
ContentsOnly 14 pages are availabe for public view
 |  | from | 163 |  |  |
| | | from | 163 | | |
Abstract
Parkinson’s disease (PD) is the 2nd most developing neuron degeneration disease disturbing elderly. Neuro-inflammation and oxidative stress are known to initiate its underlying pathogenesis which may develop behavioral and intellectual functional impediment. Symptomatic drugs particularly l-dopa have a dramatic effect in upgrading the patient{u2019}s quality of life. However, patients suffer certain motor disabilities after about 5-10 years of the disease. In the current study, effects of vitamin D (VD) or boswellia serrata (BS) extract unaccompanied or accompanied with L-dopa (5 mg/kg) on behavioral impairment, oxidative stress, neurotransmitters, neuroinflammatory and anti-inflammatory biomarkers together with glial derived neurotrophic factor (GDNF) were investigated in the rotenone{u2019}s animal model of PD. The animals were randomly assigned to normal control, dimethylesulfoxide (DMSO), and 7 rotenone treated groups (1.5 mg/kg/every other day, s.c.); one of them served as PD control and the other 6 groups were treated either with L-dopa (10 mg/kg/day, p.o.), L-dopa (5 mg/kg/day, p.o.), VD (42 I.U./kg/day, p.o.), BS (100 mg/kg/day, p.o.), VD (42 I.U./kg/day, p.o.) + L-dopa (5mg/kg/day, p.o.) or BS (100 mg/kg/day, p.o.) + L-dopa (5 mg/kg/day, p.o.) for 4 weeks. Motor behavior was assessed by open field, wire hanging, pole and rotarod tests. Oxidative stress (malondialdehyde, superoxide dismutase and lactate dehydrogenase),neurotransmitters (dopamine and glutamate), neuroinflammatory (tumor necrosis factor-alpha and inerleukin-1beta), anti-inflammatory (interleukin-10 and transforming growth factor-Ý1) biomarkers, as well as the glial derived neurotrophic factor GDNF were measured in striatal homogenate